P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI-C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)

• Kiyoshi Ando,
• Laimonas Griškevičius,
• Takayuki Ikezoe,
• Yoshikazu Ito,
• Masayoshi Masuko,
• Yasutaka Ueda,
• Morten Bagger,
• Rambabu Danekula,
• Izabela Rozenberg,
• Guido Junge,
• Jiri Mayer

Affiliations

Kiyoshi Ando

1 Tokai University School of Medicine, Isehara, Japan,

Laimonas Griškevičius

2 Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania,

Takayuki Ikezoe

3 Fukushima Medical University Hospital, Fukushima, Japan,

Yoshikazu Ito

4 Tokyo Medical University Hospital, Tokyo, Japan,

Masayoshi Masuko

5 Niigata University Medical and Dental Hospital, Niigata, Japan,

Yasutaka Ueda

6 Osaka University Hospital, Osaka, Japan,

Morten Bagger

7 Novartis Institutes for Biomedical Research, Basel, Switzerland,

Rambabu Danekula

7 Novartis Institutes for Biomedical Research, Basel, Switzerland,

Izabela Rozenberg

7 Novartis Institutes for Biomedical Research, Basel, Switzerland,

Guido Junge

7 Novartis Institutes for Biomedical Research, Basel, Switzerland,

Jiri Mayer

8 University Hospital Brno and Masaryk University, Brno, Czech Republic